Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics
Open Access
- 1 January 2019
- journal article
- review article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 2 (4) , 1069-1085
Abstract
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.Keywords
This publication has 100 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumBritish Journal of Cancer, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancerOncogene, 2010
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their SurvivalCell, 2009
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell GrowthCell Metabolism, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004